Publications

@article{Koita2024,

title = {Increasing the uptake of Intermittent Preventive Treatment of malaria in pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP) through seasonal malaria chemoprevention channel delivery: protocol of a multicenter cluster randomized implementation trial in Mali and Burkina Faso},

author = {Kadiatou Koita and Joel D. Bognini and Efundem Agboraw and Mahamadou Demb\'{e}l\'{e} and Seydou Yabr\'{e} and Bi\'{e}bo Bihoun and Oumou Coulibaly and Hamidou Niangaly and Jean Batiste N’Takp\'{e} and Maia Lesosky and Dario Scaramuzzi and Eve Worrall and Jenny Hill and Val\'{e}rie Briand and Halidou Tinto and Kassoum Kayentao},

url = {https://pubmed.ncbi.nlm.nih.gov/38166711/},

doi = {10.1186/S12889-023-17529-Z},

issn = {1471-2458},

year  = {2024},

date = {2024-01-01},

journal = {BMC public health},

volume = {24},

issue = {1},

publisher = {BMC Public Health},

abstract = {Background: The uptake of Intermittent Preventive Treatment of malaria in pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP) remains unacceptably low, with more than two-thirds of pregnant women in sub-Saharan Africa still not accessing the three or more doses recommended by the World Health Organisation (WHO). In contrast, the coverage of Seasonal Malaria Chemoprevention (SMC), a more recent strategy recommended by the WHO for malaria prevention in children under five years living in Sahelian countries with seasonal transmission, including Mali and Burkina-Faso, is high (up to 90%). We hypothesized that IPTp-SP delivery to pregnant women through SMC alongside antenatal care (ANC) will increase IPTp-SP coverage, boost ANC attendance, and increase public health impact. This protocol describes the approach to assess acceptability, feasibility, effectiveness, and cost-effectiveness of the integrated strategy. Methods and analysis: This is a multicentre, cluster-randomized, implementation trial of IPTp-SP delivery through ANC + SMC vs ANC alone in 40 health facilities and their catchment populations (20 clusters per arm). The intervention will consist of monthly administration of IPTp-SP through four monthly rounds of SMC during the malaria transmission season (July to October), for two consecutive years. Effectiveness of the strategy to increase coverage of three or more doses of IPTp-SP (IPTp3 +) will be assessed using household surveys and ANC exit interviews. Statistical analysis of IPT3 + and four or more ANC uptake will use a generalized linear mixed model. Feasibility and acceptability will be assessed through in-depth interviews and focus group discussions with health workers, pregnant women, and women with a child \< 12 months. Discussion: This multicentre cluster randomized implementation trial powered to detect a 45% and 22% increase in IPTp-SP3 + uptake in Mali and Burkina-Faso, respectively, will generate evidence on the feasibility, acceptability, effectiveness, and cost-effectiveness of IPTp-SP delivered through the ANC + SMC channel. The intervention is designed to facilitate scalability and translation into policy by leveraging existing resources, while strengthening local capacities in research, health, and community institutions. Findings will inform the local national malaria control policies. Trial registration: Retrospectively registered on August 11th, 2022; registration # PACTR202208844472053. Protocol v4.0 dated September 04, 2023. Trail sponsor: University of Sciences Techniques and Technologies of Bamako (USTTB), Mali.},

keywords = {Antimalarials* / therapeutic use, Burkina Faso, Chemoprevention, Child, Clinical Trial Protocol, doi:10.1186/s12889-023-17529-z, Drug Combinations, Female, Humans, Joel D Bognini, Kadiatou Koita, Kassoum Kayentao, Malaria* / drug therapy, Malaria* / prevention \& control, Mali, MEDLINE, Multicenter Studies as Topic, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Non-U.S. Gov't, Parasitic* / prevention \& control, PMC10763117, pmid:38166711, Pregnancy, Pregnancy Complications, Preschool, PubMed Abstract, Pyrimethamine / therapeutic use, Randomized Controlled Trials as Topic, Research Support, Seasons, Sulfadoxine / therapeutic use},

pubstate = {published},

tppubtype = {article}

}

@article{Sondo2023,

title = {Enhanced effect of seasonal malaria chemoprevention when coupled with nutrients supplementation for preventing malaria in children under 5 years old in Burkina Faso: a randomized open label trial},

author = {Paul Sondo and B\'{e}renger Kabor\'{e} and Toussaint Rouamba and Eulalie Compaor\'{e} and Yssimini Nad\`{e}ge Guill\`{e}ne Tibiri and Hyacinthe Abd El Latif Fa\"{i}\c{c}al Kabor\'{e} and Karim Derra and Marc Christian Tahita and Hamidou Ilboudo and Gauthier Tougri and Isma\"{i}la Bouda and Tikanou Dakyo and Hyacinthe Kafando and Florence Ou\'{e}draogo and Eli Rouamba and So Franck Hien and Adama Kazienga and Cheick Sa\"{i}d Compaor\'{e} and Estelle Bambara and Macaire Nana and Prabin Dahal and Franck Garanet and William Kabor\'{e} and Thierry L\'{e}f\`{e}vre and Philippe Guerin and Halidou Tinto},

url = {https://pubmed.ncbi.nlm.nih.gov/37853408/},

doi = {10.1186/S12936-023-04745-6},

issn = {1475-2875},

year  = {2023},

date = {2023-01-01},

journal = {Malaria journal},

volume = {22},

issue = {1},

publisher = {Malar J},

abstract = {Background: In rural African settings, most of the children under the coverage of Seasonal Malaria Chemoprevention (SMC) are also undernourished at the time of SMC delivery, justifying the need for packaging malarial and nutritional interventions. This study aimed at assessing the impact of SMC by coupling the intervention with nutrients supplementation for preventing malaria in children less than 5 years old in Burkina Faso. Methods: A randomized trial was carried out between July 2020 and June 2021 in the health district of Nanoro, Burkina Faso. Children (n = 1059) under SMC coverage were randomly assigned to one of the three study arms SMC + Vitamin A (SMC-A},

keywords = {Antimalarials* / therapeutic use, B\'{e}renger Kabor\'{e}, Burkina Faso / epidemiology, Chemoprevention, Child, Cross-Sectional Studies, Dietary Supplements, doi:10.1186/s12936-023-04745-6, Halidou Tinto, Humans, Infant, Malaria* / epidemiology, MEDLINE, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Nutrients, Paul Sondo, PMC10585892, pmid:37853408, Preschool, PubMed Abstract, Randomized controlled trial, Seasons, Vitamin A / therapeutic use},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {A Bayesian spatio-temporal framework to assess the effect of seasonal malaria chemoprevention on children under 5 years in Cameroon from 2016 to 2021 using routine data},

author = {Arnold Fottsoh Fokam and Toussaint Rouamba and Sekou Samadoulougou and Yazoume Ye and Fati Kirakoya-Samadoulougou},

url = {https://pubmed.ncbi.nlm.nih.gov/37951942/},

doi = {10.1186/S12936-023-04677-1},

issn = {1475-2875},

year  = {2023},

date = {2023-01-01},

journal = {Malaria journal},

volume = {22},

issue = {1},

publisher = {Malar J},

abstract = {Background: Malaria affects millions of Cameroonian children under 5 years of age living in the North and Far North regions. These regions bear the greatest burden, particularly for children under 5 years of age. To reduce the burden of disease in these regions, Cameroon adopted the Seasonal Malaria Chemoprevention (SMC) in 2016 and has implemented it each year since its adoption. However, no previous studies have systematically assessed the effects of this intervention in Cameroon. It is important to understand its effect and whether its implementation could be improved. This study aimed to assess the effect of SMC in Cameroon during the period 2016\textendash2021 on malaria morbidity in children under 5 years of age using routine data. Methods: Data on malaria cases were extracted from the Cameroon Health Monitoring Information System (HMIS) from January 1, 2011, to December 31, 2021. Health facilities report these data monthly on a single platform, the District Health Information System version 2 (DHIS2). Thus, a controlled interrupted time-series model in a Bayesian framework was used to evaluate the effects of the SMC on malaria morbidity. Results: SMC implementation was associated with a reduction in the incidence of uncomplicated malaria cases during the high-transmission periods from 2016 to 2021. Regarding the incidence of severe malaria during the high-transmission period, a reduction was found over the period 2016\textendash2019. The highest reduction was registered during the second year of implementation in 2017:15% (95% Credible Interval, 10\textendash19) of uncomplicated malaria cases and 51% (47\textendash54) of confirmed severe malaria cases. Conclusion: The addition of SMC to the malaria intervention package in Cameroon decreased the incidence of uncomplicated and severe malaria among children under 5 years of age. Based on these findings, this study supports the wide implementation of SMC to reduce the malaria burden in Cameroon as well as the use of routine malaria data to monitor the efficiency of the strategy in a timely manner.},

keywords = {Antimalarials* / therapeutic use, Arnold Fottsoh Fokam, Bayes Theorem, Cameroon / epidemiology, Chemoprevention, Child, doi:10.1186/s12936-023-04677-1, Fati Kirakoya-Samadoulougou, Humans, Infant, Malaria* / drug therapy, Malaria* / epidemiology, Malaria* / prevention \& control, MEDLINE, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC10640753, pmid:37951942, Preschool, PubMed Abstract, Seasons, Toussaint Rouamba},

pubstate = {published},

tppubtype = {article}

}

@article{Phiri2021-oy,

title = {The duration of protection from azithromycin against malaria,  acute respiratory, gastrointestinal, and skin infections when  given alongside seasonal malaria chemoprevention: Secondary  analyses of data from a clinical trial in hound\'{e}, Burkina  Faso, and bougouni, Mali},

author = {Mphatso Dennis Phiri and Matthew Cairns and Issaka Zongo and Frederic Nikiema and Modibo Diarra and Rakiswend\'{e} Serge Yerbanga and Amadou Barry and Amadou Tapily and Samba Coumare and Ismaila Thera and Irene Kuepfer and Paul Milligan and Halidou Tinto and Alassane Dicko and Jean Bosco Ou\'{e}draogo and Brian Greenwood and Daniel Chandramohan and Issaka Sagara},

doi = {10.1093/cid/ciaa1905},

issn = {1537-6591 1058-4838},

year  = {2021},

date = {2021-10-01},

urldate = {2021-10-01},

journal = {Clin. Infect. Dis.},

volume = {73},

number = {7},

pages = {e2379--e2386},

publisher = {Oxford University Press (OUP)},

abstract = {BACKGROUND: Mass drug administration (MDA) with azithromycin 

 (AZ) is being considered as a strategy to promote child survival 

 in sub-Saharan Africa, but the mechanism by which AZ reduces 

 mortality is unclear. To better understand the nature and extent 

 of protection provided by AZ, we explored the profile of 

 protection by time since administration, using data from a 

 household-randomized, placebo-controlled trial in Burkina Faso 

 and Mali. METHODS: Between 2014 and 2016, 30 977 children aged 

 3-59 months received seasonal malaria chemoprevention (SMC) with 

 sulfadoxine-pyrimethamine plus amodiaquine and either AZ or 

 placebo monthly, on 4 occasions each year. Poisson regression 

 with gamma-distributed random effects, accounting for the 

 household randomization and within-individual clustering of 

 illness episodes, was used to compare incidence of prespecified 

 outcomes between SMC+AZ versus SMC+placebo groups in fixed time 

 strata post-treatment. The likelihood ratio test was used to 

 assess evidence for a time-treatment group interaction. RESULTS: 

 Relative to SMC+placebo, there was no evidence of protection 

 from SMC+AZ against hospital admissions and deaths. Additional 

 protection from SMC+AZ against malaria was confined to the first 

 2 weeks post-administration (protective efficacy (PE): 24.2% 

 [95% CI: 17.8%, 30.1%]). Gastroenteritis and pneumonia were 

 reduced by 29.9% [21.7; 37.3%], and 34.3% [14.9; 49.3%], 

 respectively, in the first 2 weeks postadministration. 

 Protection against nonmalaria fevers with a skin condition 

 persisted up to 28 days: PE: 46.3% [35.1; 55.6%]. CONCLUSIONS: 

 The benefits of AZ-MDA are broad-ranging but short-lived. To 

 maximize impact, timing of AZ-MDA must address the challenge of 

 targeting asynchronous morbidity and mortality peaks from 

 different causes.},

note = {© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

PMID: 33417683 

PMCID: PMC8492219},

keywords = {Antimalarials/therapeutic use, Azithromycin, Azithromycin/therapeutic use, Burkina Faso/epidemiology, Chemoprevention, Child, child mortality, Drug Combinations, duration of protection, Humans, Infant, Malaria/drug therapy/epidemiology/prevention \& control, Mali/epidemiology, Preschool, Sahel, seasonal malaria chemoprevention, Seasons},

pubstate = {published},

tppubtype = {article}

}

@article{Chandramohan2021-qm,

title = {Seasonal malaria vaccination with or without seasonal malaria  chemoprevention},

author = {Daniel Chandramohan and Issaka Zongo and Issaka Sagara and Matthew Cairns and Rakiswend\'{e}-Serge Yerbanga and Modibo Diarra and Fr\'{e}d\'{e}ric Niki`ema and Amadou Tapily and Fr\'{e}d\'{e}ric Sompougdou and Djibrilla Issiaka and Charles Zoungrana and Koualy Sanogo and Alassane Haro and Mahamadou Kaya and Abdoul-Aziz Sienou and Seydou Traore and Almahamoudou Mahamar and Ismaila Thera and Kalifa Diarra and Amagana Dolo and Irene Kuepfer and Paul Snell and Paul Milligan and Christian Ockenhouse and Opokua Ofori-Anyinam and Halidou Tinto and Abdoulaye Djimde and Jean-Bosco Ou\'{e}draogo and Alassane Dicko and Brian Greenwood},

doi = {10.1056/NEJMoa2026330},

issn = {1533-4406 0028-4793},

year  = {2021},

date = {2021-09-09},

urldate = {2021-09-09},

journal = {N. Engl. J. Med.},

volume = {385},

number = {11},

pages = {1005--1017},

publisher = {Massachusetts Medical Society},

abstract = {BACKGROUND: Malaria control remains a challenge in many parts of 

 the Sahel and sub-Sahel regions of Africa. METHODS: We conducted 

 an individually randomized, controlled trial to assess whether 

 seasonal vaccination with RTS,S/AS01E was noninferior to 

 chemoprevention in preventing uncomplicated malaria and whether 

 the two interventions combined were superior to either one alone 

 in preventing uncomplicated malaria and severe malaria-related 

 outcomes. RESULTS: We randomly assigned 6861 children 5 to 17 

 months of age to receive sulfadoxine-pyrimethamine and 

 amodiaquine (2287 children [chemoprevention-alone group]), 

 RTS,S/AS01E (2288 children [vaccine-alone group]), or 

 chemoprevention and RTS,S/AS01E (2286 children [combination 

 group]). Of these, 1965, 1988, and 1967 children in the three 

 groups, respectively, received the first dose of the assigned 

 intervention and were followed for 3 years. Febrile seizure 

 developed in 5 children the day after receipt of the vaccine, 

 but the children recovered and had no sequelae. There were 305 

 events of uncomplicated clinical malaria per 1000 person-years 

 at risk in the chemoprevention-alone group, 278 events per 1000 

 person-years in the vaccine-alone group, and 113 events per 1000 

 person-years in the combination group. The hazard ratio for the 

 protective efficacy of RTS,S/AS01E as compared with 

 chemoprevention was 0.92 (95% confidence interval [CI], 0.84 to 

 1.01), which excluded the prespecified noninferiority margin of 

 1.20. The protective efficacy of the combination as compared 

 with chemoprevention alone was 62.8% (95% CI, 58.4 to 66.8) 

 against clinical malaria, 70.5% (95% CI, 41.9 to 85.0) against 

 hospital admission with severe malaria according to the World 

 Health Organization definition, and 72.9% (95% CI, 2.9 to 

 92.4) against death from malaria. The protective efficacy of the 

 combination as compared with the vaccine alone against these 

 outcomes was 59.6% (95% CI, 54.7 to 64.0), 70.6% (95% CI, 

 42.3 to 85.0), and 75.3% (95% CI, 12.5 to 93.0), respectively. 

 CONCLUSIONS: Administration of RTS,S/AS01E was noninferior to 

 chemoprevention in preventing uncomplicated malaria. The 

 combination of these interventions resulted in a substantially 

 lower incidence of uncomplicated malaria, severe malaria, and 

 death from malaria than either intervention alone. (Funded by 

 the Joint Global Health Trials and PATH; ClinicalTrials.gov 

 number, NCT03143218.).},

note = {Copyright © 2021 Massachusetts Medical Society.

Place: United States

PMID: 34432975},

keywords = {Amodiaquine/therapeutic use, Antimalarials/adverse effects/therapeutic use, Burkina Faso/epidemiology, Chemoprevention, Combination, Combined Modality Therapy, Double-Blind Method, Drug Combinations, Drug Therapy, Falciparum/epidemiology/mortality/prevention \& control, Febrile/etiology, Female, Hospitalization/statistics \& numerical data, Humans, Infant, Malaria, Malaria Vaccines/administration \& dosage/adverse effects, Male, Mali/epidemiology, Pyrimethamine/therapeutic use, Seasons, Seizures, Sulfadoxine/therapeutic use},

pubstate = {published},

tppubtype = {article}

}

@article{Roberts2021-gg,

title = {Seasonal patterns of malaria, genital infection, nutritional and  iron status in non-pregnant and pregnant adolescents in Burkina  Faso: a secondary analysis of trial data},

author = {Stephen A Roberts and Loretta Brabin and Halidou Tinto and Sabine Gies and Salou Diallo and Bernard Brabin},

doi = {10.1186/s12889-021-11819-0},

issn = {1471-2458},

year  = {2021},

date = {2021-09-01},

urldate = {2021-09-01},

journal = {BMC Public Health},

volume = {21},

number = {1},

pages = {1764},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: Adolescents are considered at high risk of developing iron deficiency. Studies in children indicate that the prevalence of iron deficiency increased with  malaria transmission, suggesting malaria seasonally may drive iron deficiency. This  paper examines monthly seasonal infection patterns of malaria, abnormal vaginal  flora, chorioamnionitis, antibiotic and antimalarial prescriptions, in relation to  changes in iron biomarkers and nutritional indices in adolescents living in a rural  area of Burkina Faso, in order to assess the requirement for seasonal infection  control and nutrition interventions. METHODS: Data collected between April 2011 and  January 2014 were available for an observational seasonal analysis, comprising  scheduled visits for 1949 non-pregnant adolescents (≤19 years), (315 of whom  subsequently became pregnant), enrolled in a randomised trial of periconceptional  iron supplementation. Data from trial arms were combined. Body Iron Stores (BIS)  were calculated using an internal regression for ferritin to allow for inflammation.  At recruitment 11% had low BIS (\< 0 mg/kg). Continuous outcomes were fitted to a  mixed-effects linear model with month, age and pregnancy status as fixed effect  covariates and woman as a random effect. Dichotomous infection outcomes were fitted  with analogous logistic regression models. RESULTS: Seasonal variation in malaria  parasitaemia prevalence ranged between 18 and 70% in non-pregnant adolescents  (P \< 0.001), peaking at 81% in those who became pregnant. Seasonal variation  occurred in antibiotic prescription rates (0.7-1.8 prescriptions/100 weekly visits,  P \< 0.001) and chorioamnionitis prevalence (range 15-68%, P = 0.026). Mucosal  vaginal lactoferrin concentration was lower at the end of the wet season (range  2-22 μg/ml, P \< 0.016), when chorioamnionitis was least frequent. BIS fluctuated  annually by up to 53.2% per year around the mean BIS (5.1 mg/kg(2), range  4.1-6.8 mg/kg), with low BIS (\< 0 mg/kg) of 8.7% in the dry and 9.8% in the wet  seasons (P = 0.36). Median serum transferrin receptor increased during the wet  season (P \< 0.001). Higher hepcidin concentration in the wet season corresponded  with rising malaria prevalence and use of prescriptions, but with no change in BIS.  Mean Body Mass Index and Mid-Upper-Arm-Circumference values peaked mid-dry season  (both P \< 0.001). CONCLUSIONS: Our analysis supports preventive treatment of malaria  among adolescents 15-19 years to decrease their disease burden, especially  asymptomatic malaria. As BIS were adequate in most adolescents despite seasonal  malaria, a requirement for programmatic iron supplementation was not substantiated.},

note = {© 2021. The Author(s).

PMID: 34579679 

PMCID: PMC8477466},

keywords = {Abnormal vaginal flora, Adolescents, Bacterial vaginosis, Body Mass Index, Burkina Faso/epidemiology, Child, Female, Humans, Iron, iron biomarkers, Malaria, Malaria/drug therapy/epidemiology, MUAC, Pregnancy, Seasons, Vagina},

pubstate = {published},

tppubtype = {article}

}

@article{Yameogo2021-bb,

title = {Effect of seasonal malaria chemoprevention plus azithromycin on  Plasmodium falciparum transmission: gametocyte infectivity and  mosquito fitness},

author = {Koudraogo Bienvenue Yam\'{e}ogo and Rakiswend\'{e} Serge Yerbanga and Seydou Bienvenu Ouattara and Franck A Yao and Thierry Lef`evre and Issaka Zongo and Frederic Niki`ema and Yves Daniel Compaor\'{e} and Halidou Tinto and Daniel Chandramohan and Brian Greenwood and Adrien M G Belem and Anna Cohuet and Jean Bosco Ou\'{e}draogo},

doi = {10.1186/s12936-021-03855-3},

issn = {1475-2875},

year  = {2021},

date = {2021-07-27},

urldate = {2021-07-27},

journal = {Malar. J.},

volume = {20},

number = {1},

pages = {326},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: Seasonal malaria chemoprevention (SMC) consists of administration of sulfadoxine-pyrimethamine (SP) + amodiaquine (AQ) at monthly intervals to children  during the malaria transmission period. Whether the addition of azithromycin (AZ) to  SMC could potentiate the benefit of the intervention was tested through a  double-blind, randomized, placebo-controlled trial. The effect of SMC and the  addition of AZ, on malaria transmission and on the life history traits of Anopheles  gambiae mosquitoes have been investigated. METHODS: The study included 438 children  randomly selected from among participants in the SMC + AZ trial and 198 children  from the same area who did not receive chemoprevention. For each participant in the  SMC + AZ trial, blood was collected 14 to 21 days post treatment, examined for the  presence of malaria sexual and asexual stages and provided as a blood meal to An.  gambiae females using a direct membrane-feeding assay. RESULTS: The SMC treatment,  with or without AZ, significantly reduced the prevalence of asexual Plasmodium  falciparum (LRT X(2)(2) = 69, P \< 0.0001) and the gametocyte prevalence (LRT  X(2)(2) = 54, P \< 0.0001). In addition, the proportion of infectious feeds (LRT  X(2)(2) = 61, P \< 0.0001) and the prevalence of oocysts among exposed mosquitoes  (LRT X(2)(2) = 22.8, P \< 0.001) was reduced when mosquitoes were fed on blood from  treated children compared to untreated controls. The addition of AZ to SPAQ was  associated with an increased proportion of infectious feeds (LRT X(2)(1) = 5.2,  P = 0.02), suggesting a significant effect of AZ on gametocyte infectivity. There  was a slight negative effect of SPAQ and SPAQ + AZ on mosquito survival compared to  mosquitoes fed with blood from control children (LRTX(2)(2) = 330, P \< 0.0001).  CONCLUSION: This study demonstrates that SMC may contribute to a reduction in human  to mosquito transmission of P. falciparum, and the reduced mosquito longevity  observed for females fed on treated blood may increase the benefit of this  intervention in control of malaria. The addition of AZ to SPAQ in SMC appeared to  enhance the infectivity of gametocytes providing further evidence that this  combination is not an appropriate intervention.},

note = {© 2021. The Author(s).

PMID: 34315475 

PMCID: PMC8314489},

keywords = {Amodiaquine/administration \& dosage, Animals, Antimalarials/administration \& dosage, Chemoprevention, Child, Culicidae/physiology, Drug Combinations, Falciparum/prevention \& control/transmission, Gametocytes, Genetic Fitness, Humans, Malaria, Plasmodium falciparum/physiology, Preschool, Pyrimethamine/administration \& dosage, seasonal malaria chemoprevention, Seasons, Sulfadoxine/administration \& dosage, Transmission},

pubstate = {published},

tppubtype = {article}

}

@article{De_Wit2021-yi,

title = {Nutritional status in young children prior to the malaria  transmission season in Burkina Faso and Mali, and its impact on  the incidence of clinical malaria},

author = {Mariken Wit and Matthew Cairns and Yves Daniel Compaor\'{e} and Issaka Sagara and Irene Kuepfer and Issaka Zongo and Amadou Barry and Modibo Diarra and Amadou Tapily and Samba Coumare and Ismaila Thera and Frederic Nikiema and R Serge Yerbanga and Rosemonde M Guissou and Halidou Tinto and Alassane Dicko and Daniel Chandramohan and Brian Greenwood and Jean Bosco Ouedraogo},

doi = {10.1186/s12936-021-03802-2},

issn = {1475-2875},

year  = {2021},

date = {2021-06-22},

urldate = {2021-06-22},

journal = {Malar. J.},

volume = {20},

number = {1},

pages = {274},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: Malaria and malnutrition remain major problems in 

 Sahel countries, especially in young children. The direct effect 

 of malnutrition on malaria remains poorly understood, and may 

 have important implications for malaria control. In this study, 

 nutritional status and the association between malnutrition and 

 subsequent incidence of symptomatic malaria were examined in 

 children in Burkina Faso and Mali who received either 

 azithromycin or placebo, alongside seasonal malaria 

 chemoprevention. METHODS: Mid-upper arm circumference (MUAC) was 

 measured in all 20,185 children who attended a screening visit 

 prior to the malaria transmission season in 2015. Prior to the 

 2016 malaria season, weight, height and MUAC were measured among 

 4149 randomly selected children. Height-for-age, weight-for-age, 

 weight-for-height, and MUAC-for-age were calculated as 

 indicators of nutritional status. Malaria incidence was measured 

 during the following rainy seasons. Multivariable random effects 

 Poisson models were created for each nutritional indicator to 

 study the effect of malnutrition on clinical malaria incidence 

 for each country. RESULTS: In both 2015 and 2016, nutritional 

 status prior to the malaria season was poor. The most prevalent 

 form of malnutrition in Burkina Faso was being underweight 

 (30.5%; 95% CI 28.6-32.6), whereas in Mali stunting was most 

 prevalent (27.5%; 95% CI 25.6-29.5). In 2016, clinical malaria 

 incidence was 675 per 1000 person-years (95% CI 613-744) in 

 Burkina Faso, and 1245 per 1000 person-years (95% CI 1152-1347) 

 in Mali. There was some evidence that severe stunting was 

 associated with lower incidence of malaria in Mali (RR 0.81; 95% CI 0.64-1.02; p = 0.08), but this association was not seen 

 in Burkina Faso. Being moderately underweight tended to be 

 associated with higher incidence of clinical malaria in Burkina Faso (RR 1.27; 95% CI 0.98-1.64; p = 0.07), while this was the 

 case in Mali for moderate wasting (RR 1.27; 95% CI 0.98-1.64; p = 0.07). However, these associations were not observed in 

 severely affected children, nor consistent between countries. 

 MUAC-for-age was not associated with malaria risk. CONCLUSIONS: 

 Both malnutrition and malaria were common in the study areas, 

 high despite high coverage of seasonal malaria chemoprevention 

 and long-lasting insecticidal nets. However, no strong or 

 consistent evidence was found for an association between any of 

 the nutritional indicators and the subsequent incidence of 

 clinical malaria.},

note = {PMID: 34158054 

PMCID: PMC8220741},

keywords = {Acute malnutrition, Antimalarials/administration \& dosage, Azithromycin/administration \& dosage, Burkina Faso, Burkina Faso/epidemiology, Child, Chronic malnutrition, Female, Humans, Incidence, Infant, Malaria, Malaria/epidemiology/transmission, Male, Nutritional Status, Preschool, seasonal malaria chemoprevention, Seasons},

pubstate = {published},

tppubtype = {article}

}

@article{Sondo2021-kc,

title = {Assessment of a combined strategy of seasonal malaria  chemoprevention and supplementation with vitamin A, zinc and  Plumpy'Doz™ to prevent malaria and malnutrition in children  under 5 years old in Burkina Faso: a randomized open-label trial  (SMC-NUT)},

author = {Paul Sondo and Marc Christian Tahita and Toussaint Rouamba and Karim Derra and B\'{e}renger Kabor\'{e} and Cheick Sa"id Compaor\'{e} and Florence Ou\'{e}draogo and Eli Rouamba and Hamidou Ilboudo and Estelle A"issa Bambara and Macaire Nana and Edmond Yabr\'{e} Sawadogo and Hermann Sorgho and Athanase Mwinessobaonfou Som\'{e} and Innocent Val\'{e}a and Prabin Dahal and Maminata Traor\'{e}/Coulibaly and Halidou Tinto},

doi = {10.1186/s13063-021-05320-7},

issn = {1745-6215},

year  = {2021},

date = {2021-05-24},

urldate = {2021-05-24},

journal = {Trials},

volume = {22},

number = {1},

pages = {360},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: Malaria and malnutrition represent major public 

 health concerns worldwide especially in Sub-Sahara Africa. 

 Despite implementation of seasonal malaria chemoprophylaxis 

 (SMC), an intervention aimed at reducing malaria incidence among 

 children aged 3-59 months, the burden of malaria and associated 

 mortality among children below age 5 years remains high in 

 Burkina Faso. Malnutrition, in particular micronutrient 

 deficiency, appears to be one of the potential factors that can 

 negatively affect the effectiveness of SMC. Treating 

 micronutrient deficiencies is known to reduce the incidence of 

 malaria in highly prevalent malaria zone such as rural settings. 

 Therefore, we hypothesized that a combined strategy of SMC 

 together with a daily oral nutrients supplement will enhance the 

 immune response and decrease the incidence of malaria and 

 malnutrition among children under SMC coverage. METHODS: 

 Children (6-59 months) under SMC coverage receiving vitamin A 

 supplementation will be randomly assigned to one of the three 

 study arms (a) SMC + vitamin A alone, (b) SMC + vitamin A + 

 zinc, or (c) SMC + vitamin A + Plumpy'Doz™ using 1:1:1 

 allocation ratio. After each SMC monthly distribution, children 

 will be visited at home to confirm drug administration and 

 followed-up for 1 year. Anthropometric indicators will be 

 recorded at each visit and blood samples will be collected for 

 microscopy slides, haemoglobin measurement, and spotted onto 

 filter paper for further PCR analyses. The primary outcome 

 measure is the incidence of malaria in each arm. Secondary 

 outcome measures will include mid-upper arm circumference and 

 weight gain from baseline measurements, coverage and compliance 

 to SMC, occurrence of adverse events (AEs), and prevalence of 

 molecular markers of antimalarial resistance comprising Pfcrt, 

 Pfmdr1, Pfdhfr, and Pfdhps. DISCUSSION: This study will 

 demonstrate an integrated strategy of malaria and malnutrition 

 programmes in order to mutualize resources for best impact. By 

 relying on existing strategies, the policy implementation of 

 this joint intervention will be scalable at country and regional 

 levels. TRIAL REGISTRATION: ClinicalTrials.gov NCT04238845 . 

 Registered on 23 January 2020 

 https://clinicaltrials.gov/ct2/show/NCT04238845.},

note = {PMID: 34030705 

PMCID: PMC8142067},

keywords = {Antimalarials/adverse effects, Burkina Faso/epidemiology, Chemoprevention, Child, Child Nutrition Disorders, Dietary Supplements, Humans, Infant, Malaria, Malaria/diagnosis/epidemiology/prevention \& control, Malnutrition, Malnutrition/diagnosis/drug therapy/prevention \& control, Pharmaceutical Preparations, Plumpy’Doz™, Preschool, Randomized controlled trial, Seasonal chemoprevention, Seasons, Vitamin A, Vitamin A/adverse effects, Zinc},

pubstate = {published},

tppubtype = {article}

}

@article{Lompo2021-sk,

title = {Pathogens associated with acute diarrhea, and comorbidity with  malaria among children under five years old in rural Burkina  Faso},

author = {Palpouguini Lompo and Marc Christian Tahita and Hermann Sorgho and William Kabor\'{e} and Adama Kazienga and Ashmed Cheick Bachirou Nana and Hamtandi Magloire Natama and Isidore Juste Ouindgueta Bonkoungou and Nicolas Barro and Halidou Tinto},

doi = {10.11604/pamj.2021.38.259.15864},

issn = {1937-8688},

year  = {2021},

date = {2021-03-01},

urldate = {2021-03-01},

journal = {Pan Afr. Med. J.},

volume = {38},

pages = {259},

publisher = {Pan African Medical Journal},

abstract = {INTRODUCTION: acute diarrhea in children under five years is a public health problem in developing countries and particularly in malaria-endemic areas where both  diseases co-exist. The present study examined the etiology of childhood diarrhea and  its comorbidity with malaria in a rural area of Burkina Faso. 

METHODS: conventional  culture techniques, direct stools examination, and viruses´ detection by rapid tests  were performed on the fresh stools and microscopy was used to diagnose malaria. Some  risk factors were also assessed. RESULTS: on a total of 191 samples collected, at  least one pathogen was identified in 89 cases (46.6%). The proportions of pathogens  found on the 89 positive stool samples were parasites 51.69% (46 cases), viruses  39.33% (35 cases), and bacteria 14.61% (13 cases), respectively. The relationship  between malaria and infectious diarrhea was significant in viral and parasites  causes (p=0.005 and 0.043 respectively). Fever, vomiting and abdominal pain were the  major symptoms associated with diarrhea, with 71.51%, 31.72% and 23.66%  respectively. The highest viral diarrhea prevalence was reported during the dry  season (OR=5.29, 95% CI: 1.74 - 16.07, p=0.001) while parasite diarrhea was more  encountered during the rainy season (OR=0.41, 95% CI: 0.33 - 0.87, p=0.011).  CONCLUSION: Giardia spp and rotavirus were the leading cause of acute diarrhea in  Nanoro, Burkina Faso with a predominance of rotavirus in children less than 2 years.  Parasite and viral diarrhea were the most pathogens associated with malaria.  However, the high rate of negative stool samples suggests the need to determine  other enteric microorganisms.},

note = {Copyright: Palpouguini Lompo et al.

PMID: 34104307 

PMCID: PMC8164431},

keywords = {Abdominal Pain/epidemiology, Acute Disease, bacteria, Burkina Faso, Burkina Faso/epidemiology, Child, Comorbidity, Diarrhea, Diarrhea/epidemiology/microbiology, Female, Fever/epidemiology, Giardiasis/epidemiology, Humans, Infant, infectious, Malaria, Malaria/epidemiology, Male, parasite, pathogens, Preschool, Prevalence, Risk Factors, rotavirus, Rotavirus Infections/epidemiology, Rural Population, Seasons, Vomiting/epidemiology},

pubstate = {published},

tppubtype = {article}

}

@article{Ouedraogo2020-vc,

title = {A microplanning model to improve door-to-door health service  delivery: the case of Seasonal Malaria Chemoprevention in  Sub-Saharan African villages},

author = {Andr\'{e} Lin Ou\'{e}draogo and Julie Zhang and Halidou Tinto and Innocent Val\'{e}a and Edward A Wenger},

doi = {10.1186/s12913-020-05972-2},

issn = {1472-6963},

year  = {2020},

date = {2020-12-07},

urldate = {2020-12-01},

journal = {BMC Health Serv. Res.},

volume = {20},

number = {1},

pages = {1128},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: Malaria incidence has plateaued in Sub-Saharan 

 Africa despite Seasonal Malaria Chemoprevention's (SMC) 

 introduction. Community health workers (CHW) use a door-to-door 

 delivery strategy to treat children with SMC drugs, but for SMC 

 to be as effective as in clinical trials, coverage must be high 

 over successive seasons. METHODS: We developed and used a 

 microplanning model that utilizes population raster to estimate 

 population size, generates optimal households visit itinerary, 

 and quantifies SMC coverage based on CHWs' time investment for 

 treatment and walking. CHWs' performance under current SMC 

 deployment mode was assessed using CHWs' tracking data and 

 compared to microplanning in villages with varying demographics 

 and geographies. RESULTS: Estimates showed that microplanning 

 significantly reduces CHWs' walking distance by 25%, increases 

 the number of visited households by 36% (p \< 0.001) and 

 increases SMC coverage by 21% from 37.3% under current SMC 

 deployment mode up to 58.3% under microplanning (p \< 0.001). 

 Optimal visit itinerary alone increased SMC coverage up to 100% 

 in small villages whereas in larger or hard-to-reach villages, 

 filling the gap additionally needed an optimization of the CHW 

 ratio. CONCLUSION: We estimate that for a pair of CHWs, the 

 daily optimal number of visited children (assuming 8.5mn spent 

 per child) and walking distance should not exceed 45 (95% CI 

 27-62) and 5 km (95% CI 3.2-6.2) respectively. Our work 

 contributes to extend SMC coverage by 21-63% and may have 

 broader applicability for other community health programs.},

note = {PMID: 33287825 

PMCID: PMC7720067},

keywords = {Africa South of the Sahara/epidemiology, Antimalarials/therapeutic use, Burkina Faso, Chemoprevention, Child, CHW, Community health worker, Door-to-door, Health Services, Humans, Malaria, Malaria/drug therapy/epidemiology/prevention \& control, Microplanning, Model, Satellite imagerySeasonal malaria chemoprevention, Seasons, SMC},

pubstate = {published},

tppubtype = {article}

}